Stanford University
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Inclusion Criteria (Arm A) \* Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma Who either: * Experienced refractory or relapsed disease, treated with standard chemotherapy, without immunotherapy treatment. OR * Previously undergone standard of care immunotherapy with FDA approved therapies, such as Kymriah™ (CTL019, tisagenlecleucel), blinatumomab or * Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age. Inclusion Criteria (Arm B) * Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell l…
Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.